Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review

Hartwig, Susanne; Syrjänen, Stina; Dominiak-Felden, Geraldine; Brotons, María; Castellsagué, Xavier

doi:10.1186/1471-2407-12-30

Cited by 166 publications

(128 citation statements)

References 79 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…1 It is causally associated with cervical cancer, penile cancer, vulval cancer, oropharyngeal cancer and anal cancer. 2 The prevalence of HPV infection is greater in MSM, particularly in HIV-infected MSM compared to the general population. 3,4,5 The reported incidence of anal cancer in MSM is up to 35 cases per 100,000 6 and up to 131 cases per 100,000 in HIVinfected MSM.…”

Section: Introductionmentioning

confidence: 99%

HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland

Sadlier

Lynam

O’Dea

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background Men who have sex with men (MSM), particularly HIV-infected MSM are disproportionately affected by HPV infection and associated disease. The HPV vaccine has potential to greatly reduce the burden of HPV-associated disease including anal cancer in MSM. The efficacy of the HPV vaccine is dependent on high levels of vaccine uptake. The aim of this study was to examine HPV vaccine acceptability and factors influencing vaccine acceptability in MSM in Ireland. Methods A self-administered survey was distributed to HIV-infected and HIV negative MSM examining HPV vaccine acceptability and factors associated with vaccine acceptability. Logistic regression was used to identify key variables and predictors of HPV vaccine acceptability. Results 302 MSM participated in the study. Acceptability of HPV vaccine was 31% (unconditional), 51% (conditional on stated efficacy and a cost of €300), 65% (conditional on stated efficacy and a cost of €100) and 78% (conditional on stated efficacy and no cost). Cost was negatively associated with HPV vaccine acceptability (p<0.01) while knowledge of HPV vaccine efficacy was significantly associated with vaccine acceptability, even in the context of associated cost (p<0.01). Conclusions Acceptability of HPV vaccine in MSM in Ireland is high based on no cost vaccine and on stated vaccine efficacy (78%). Cost is negatively associated with vaccine acceptability. Understanding levels of knowledge of HPV infection, HPV associated disease and attitudes toward HPV vaccination are important as they will contribute to HPV vaccine acceptability among MSM and will help guide effective preventive programs.

show abstract

Section: Introductionmentioning

confidence: 99%

HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland

Sadlier

Lynam

O’Dea

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…As in invasive cervical carcinoma, HPV16 is causally linked to AC, and in European men, it is detected in 87.1% of the cases, while HPV18 is reported in only 6.2% of them (1,10).…”

mentioning

confidence: 99%

Anal Human Papillomavirus Genotype Distribution in HIV-Infected Men Who Have Sex with Men by Geographical Origin, Age, and Cytological Status in a Spanish Cohort

et al. 2013

View full text Add to dashboard Cite

“…Además, la mayoría de casos ocurren en mujeres jóvenes (menores de 25 años) (6) . Se ha estimado, también, que el 99% de los casos de cáncer de cuello uterino (CCU) tienen presencia de VPH de alto riesgo oncológico (7) y 70% específicamente de los genotipos 16 y 18 (8) . Además, el 90% de los casos de VAG se deben a los genotipos 6 y 11 (9) .…”

Section: Introductionunclassified

“…Se han reportado incidencias que van desde 58 hasta 319 casos por 100 000 personas, la mayoría de casos en mujeres (8,15,16) .…”

Section: Introductionunclassified

Evaluación costo-efectividad de dos alternativas de vacunación para el virus del papiloma humano en la prevención del cáncer cervical uterino

Bolaños-Díaz

Tejada

Beltrán

et al. 2016

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

Objetivos. Determinar la relación costo-efectividad de la vacunación contra el (virus del papiloma humano) VPH y el tamiz de lesiones cervicales, frente a un programa de tamiz solo. Materiales y métodos. Se realizó una evaluación costoefectividad y se empleó un modelo de Markov, con un horizonte temporal de 70 años y tres alternativas de prevención para el (cáncer del cuello uterino) CCU (tamiz solo, tamiz + vacuna bivalente, y tamiz + vacuna cuadrivalente), en una cohorte hipotética de niñas de diez años, desde la perspectiva del Ministerio de Salud. Resultados. La vacunación contra el VPH y tamiz es más costo-efectiva que el tamiz solo a partir de una voluntad de pago de S/ 2000 (USD 1 290,32). En el análisis determinístico, la vacuna bivalente es marginalmente más costo-efectiva que la vacuna cuadrivalente (S/ 48 [USD 30,97] frente a S/ 166 [USD 107,10] por AVAC, respectivamente). Sin embargo, en el análisis probabilístico ambas intervenciones generan nubes de puntos superpuestos, con una tendencia de la vacuna cuadrivalente a ser más costo-efectiva. Es decir, ambas son costo-efectivas y, por ende, intercambiables. El modelo fue especialmente sensible a variaciones de la cobertura y en la prevalencia de infección persistente por genotipos oncológicos no incluidos en la vacuna. Conclusiones. A partir de una disponibilidad de pago de S/ 2000 [USD 1 290,32] el tamiz y la vacunación son más costo-efectivos que el tamiz solo. La diferencia de costo-efectividad entre ambas vacunas carece de robustez probabilística y ambas vacunas pueden considerarse intercambiables desde la perspectiva costo-efectividad. Palabras clave: Vacunas contra papillomavirus; Neoplasias del cuello uterino; Condiloma acuminado; Análisis costobeneficio (Fuente: DeCS BIREME). EVALUATION OF THE COST-EFFECTIVENESS OF TWO ALTERNATIVE HUMAN PAPILLOMAVIRUS VACCINES AS PROPHYLAXIS AGAINST UTERINE CERVICAL CANCER ABSTRACTObjectives. To determine the cost-effectiveness of human papillomavirus (HPV) vaccination and cervical lesion screening versus screening alone for the prevention of uterine cervical cancer (UCC). Materials and methods. This cost-effectiveness evaluation from the perspective of the Ministry of Health employed a Markov model with a 70-year time horizon and three alternatives for UCC prevention (screening alone, screening + bivalent vaccine, and screening + quadrivalent vaccine) in a hypothetical cohort of 10-year-old girls. Results. Our model, which was particularly sensitive to variations in coverage and in the prevalence of persistent infection by oncologic genotypes not included in the vaccine, revealed that HPV vaccination and screening is more cost-effective than screening alone, assuming a payment availability from S/ 2 000 (US dollars (USD) 1 290.32) per subject. In the deterministic analysis, the bivalent vaccine was marginally more cost-effective than the quadrivalent vaccine (S/ 48 [USD 30.97] vs. S/ 166 [USD 107.10] per quality-adjusted life-year, respectively). However, in the probabilistic analysis, both interventions ge...

show abstract

Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review

Cited by 166 publications

References 79 publications

HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland

HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland

Anal Human Papillomavirus Genotype Distribution in HIV-Infected Men Who Have Sex with Men by Geographical Origin, Age, and Cytological Status in a Spanish Cohort

Evaluación costo-efectividad de dos alternativas de vacunación para el virus del papiloma humano en la prevención del cáncer cervical uterino

Contact Info

Product

Resources

About